A 1 -A 2 9 8 test score indicating likely benefit from chemotherapy, doctor's estimate of risk of cancer returning (based on clinical algorithms), likelihood of permanent side effects, trust in cancer treatment doctor, and likelihood of temporary side effects. In a scenario of intermediate risk of cancer returning based on clinical algorithms alone (no GEP score), 12% of respondents chose chemotherapy compared to 89% of respondents with a GEP score of 44 (high likelihood of benefit from chemotherapy). CONCLUSIONS: GEP testing is highly valued and strongly influences chemotherapy treatment decisions in all three groups. These findings provide preliminary evidence supporting the clinical utility of GEP in BrCa treatment decisions. 
PCN112

USE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-ANEMIA (FACT-AN) INSTRUMENT IN PERSONS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA
OBJECTIVES:
Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a cancer in which anemia is common. The Functional Assessment of Cancer Therapy (FACT) -Anemia instrument measures general quality of life (QOL) and anemia-related concerns of people with cancer. We assessed the relationship between anemia response to therapy with pomalidomide and domains of the FACT-An instrument. METHODS: Data were from a phase-2 randomized doubleblind Bayesian "pick-the-winner" trial of pomalidomide and prednisone in subjects with MPN-associated myelofibrosis and anemia (including RBCtransfusion-dependence). Details of the study, including definitions of anemia response, RBC-transfusion-dependence and -independence are reported. Change in QOL from randomization to the last cycle of therapy was evaluated using the FACT-An physical well-being (PWB), functional well-being (FWB), trial outcome index (TOI) and anemia (An) domains. Minimally clinically important differences (MID) were used to determine the smallest difference in scores which subjects perceived as beneficial in the FACT-An domains of interest. Subjects were classified as meeting MID for responsiveness if their change score from baseline was greater than one standard error of measurement (SEM) indicating improvement. RESULTS: Eighty-five subjects were studied. All FACT-An domains showed strong reliability as measured by Cronbach alpha (PWB α=0.77, FWB α=0.87, An α=0.92, TOI α=0.95). Thirty-one subjects were classified as anemia responders by clinical and laboratory criteria. Anemia responders showed greater improvement in PWB, FWB and TOI scores than non-responders across all FACT-An domains. Improvement began at the second 28 day cycle of therapy and was sustained. CONCLUSIONS: We show anemia response correlates with improved QOL measured by the FACT-An instrument in persons with MPNassociated myelofibrosis receiving pomalidomide. 
PCN113 ASSESSING THE IMPACT OF PATIENT-REPORTED OUTCOMES AND HEALTH ECONOMIC BENEFIT CLAIMS ON THE MARKET VALUE OF ONCOLOGIC PHARMACEUTICALS
OBJECTIVES:
To evaluate the impact that patient-reported outcomes (PRO) and health economic (HE) benefit claims made in product labels and in published literature have on market value of oncologic pharmaceuticals in the US. METHODS: A target list of 13 advanced/metastatic cancers and 32 drugs with labeled indications for them were combined into 37 unique "drug-indication pairs." Drugs were antineoplastic agents with FDA approval ≤ 2009. PRO claims in US and EMA labels were identified through a commercial research database. PRO and HE claims made in published literature were identified through review of abstracts published 2000-2010. Economic data (i.e., market size and market share in 2010) for drug-indication pairs were extracted from MarketScan ® claims databases. Data were compiled into an analytic file and one primary and four secondary regression models were specified, adjusting for relative drug safety and efficacy. The dependant variable in each model represented dollar-value market share in 2010 of each drug in its cancer indication. RESULTS: Results indicate that PRO claims in US product labels are associated with positive increases in market value of oncologic pharmaceuticals. Presence of a label PRO claim was associated with 66% increase in market share-about the same economic impact conferred by superior drug efficacy. Results were not statistically significant in the model for US labels alone (p<0.18), but were significant when combining US and EMA labels (p<0.03). No significant association was found between PRO and HE claims made in published literature and market value of oncologic pharmaceuticals. CONCLUSIONS: Our analysis fills gaps in understanding the economic value of PRO and HE benefit claims for oncologic pharmaceuticals and sets precedence for undertaking similar studies in oncology and other disease areas. Results reinforce that industry should carefully evaluate potential positive returns for investing in inclusion of PRO and HE endpoints in clinical trials.
PCN115 PHASE IB STUDY OF PATIENTS RECEIVING TOPOTECAN BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS: NEUROCOGNITIVE FUNCTIONING AND QUALITY OF LIFE OUTCOMES
Oberg JA, Dave A, Bruce JN, Sands SA Columbia University, New York, NY, USA OBJECTIVES: Malignant gliomas are highly proliferative, invasive tumors that are resistant to conventional treatment and are typically accompanied by progressive physical and mental debilitation. We evaluated neurocognitive functioning (NCF) and quality of life (QOL) as part of a prospective Phase Ib doseescalation study of topotecan by CED in patients with recurrent gliomas. METHODS: Secondary data analysis was conducted on the 16 patients enrolled on the Phase Ib study. Independent-sample t-tests were used to explore differences. Patients received serial assessments at baseline, 1-, 2-, 3-, and 4-months post-treatment. NCF and QOL were assessed using the HeadMinder Cognitive Stability Index and the SF-36, respectively. RESULTS: Patients were predominantly male (68.7%) with a median age of 50 years (Range=22-71 years). Tumor volume and total infused dose of topotecan were not associated with any of the outcome variables. NCF was better for early responders (ERs) than patients with progressive disease (PD) or pseudoprogression (PP). Processing speed for ERs (n=4) averaged over the follow-up period was significantly higher (z=1.95 SD) than patients with PD (n=5; z=-0.61 SD) (p=0.006). Similarly, change in response time was better for ERs compared to those with PD (z=4.40 SD; z=-0.52, respectively; p=0.04). At baseline, SF-36 results for physical and mental QOL were within normal limits. Relative to baseline, average change in SF-36 scores posttreatment suggest that overall mental QOL was significantly higher for ERs (MCS change score=5.04) than patients with PD (MCS change score=-6.48) (p=0.02), reflecting better emotional well-being. Average change in physical QOL was not significantly different between ERs, PD or PP. CONCLUSIONS: These results provide the beginning framework to better understand NCF/QOL outcomes in patients with recurrent malignant gliomas treated with topotecan by CED. Continued monitoring of these outcomes will be important in the phase II trial to assess treatment efficacy and impact on NCF and QOL. 
PCN116 ESTIMATION OF POTENTIAL GAIN IN QUALITY OF LIFE FROM EARLY DETECTION OF CERVICAL CANCER
OBJECTIVES:
To compare dynamic changes of the health-related quality of life (HRQL) in patients with invasive cervical cancer and carcinoma in situ for estimation of potential gain in quality of life from early detection. METHODS: All patients diagnosed with cervical cancer who visited the cancer clinic at the National Cheng Kung University Hospital from March 2012 to September 2012 were invited to participate in the study. They were classified into 4 groups according to treatment modalities: Carcinoma in situ post conization, invasive cancer treated with operation only, those treated with operation plus chemotherapy or radiotherapy, and those treated with chemotherapy or radiotherapy only. The WHOQOL-BREF (World Health Organization Quality of Life -brief version) questionnaire was used to measure the HRQL. The dynamic changes of HRQL scores were calculated with the kernel smoothing method. A mixed-effect model was constructed to analyze repeated measurements and determine risk factors for impairment of HRQL and different treatment modalities. RESULTS: A total of 507 measurements were collected from 421 patients. In comparison with carcinoma-in-situ patients post conization, patients with invasive cervical cancer who received operation plus chemotherapy or radiotherapy showed consistently lower scores in facets of physical and psychological domains and sexual activities after adjustment for age, education, marital status, co-morbidities and duration after diagnosis. The differences in scores seemed to be reduced temporarily 4-8 years after diagnosis. CONCLUSIONS: Early detection of cervical cancer may avoid impairment of quality of life in physical, psychological domains, and sexual activities.
